Diabetic retinopathy: Looking forward to 2030.
| Autor: | Tan TE; Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore.; Duke-NUS Medical School, Singapore, Singapore., Wong TY; Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore.; Duke-NUS Medical School, Singapore, Singapore.; Tsinghua Medicine, Tsinghua University, Beijing, China. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2023 Jan 09; Vol. 13, pp. 1077669. Date of Electronic Publication: 2023 Jan 09 (Print Publication: 2022). |
| DOI: | 10.3389/fendo.2022.1077669 |
| Abstrakt: | Diabetic retinopathy (DR) is the major ocular complication of diabetes mellitus, and is a problem with significant global health impact. Major advances in diagnostics, technology and treatment have already revolutionized how we manage DR in the early part of the 21 st century. For example, the accessibility of imaging with optical coherence tomography, and the development of anti-vascular endothelial growth factor (VEGF) treatment are just some of the landmark developments that have shaped the DR landscape over the last few decades. Yet, there are still more exciting advances being made. Looking forward to 2030, many of these ongoing developments are likely to further transform the field. First, epidemiologic projections show that the global burden of DR is not only increasing, but also shifting from high-income countries towards middle- and low-income areas. Second, better understanding of disease pathophysiology is placing greater emphasis on retinal neural dysfunction and non-vascular aspects of diabetic retinal disease. Third, a wealth of information is becoming available from newer imaging modalities such as widefield imaging systems and optical coherence tomography angiography. Fourth, artificial intelligence for screening, diagnosis and prognostication of DR will become increasingly accessible and important. Fifth, new pharmacologic agents targeting other non-VEGF-driven pathways, and novel therapeutic strategies such as gene therapy are being developed for DR. Finally, the classification system for diabetic retinal disease will need to be continually updated to keep pace with new developments. In this article, we discuss these major trends in DR that we expect to see in 2030 and beyond. Competing Interests: TYW is a coinventor, with patents pending, for a deep learning system for diabetic retinopathy, glaucoma, and age-related macular degeneration (SG Non-Provisional Application number 10201706186V), and a computer-implemented method for training an image classifier using weakly annotated training data (SG Provisional Patent Application number 10201901083Y), and is cofounder and shareholder of EyRIS Pte Ltd, Singapore. The remaining author declares that the research was conducted in the absence of any other commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Tan and Wong.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|